France’s First Ever Hobby Shop Focused on GUNPLA: BANDAI HOBBY STORE
27.7.2020 10:00:00 EEST | Business Wire | Press release
BANDAI S.A.S. (President & CEO: Susumu Hirasawa; Head office: Tour W 102, Terrasse Boieldieu 92085 Paris La Defense cedex France) of the BANDAI NAMCO Group, Manga Story SARL (President & CEO: Patrick Carosella; Head office: 13 Boulevard Voltaire, 75011 Paris, France), and BANDAI SPIRITS CO., LTD. (President & CEO: Yusuke Fukuda; Head office: Minato-ku, Tokyo) will open the BANDAI HOBBY STORE, France's first ever hobby shop centered around GUNPLA, in the central Republic district of Paris, France on July 30, 2020.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200727005200/en/
BANDAI HOBBY STORE interior image. It may differ in part from the actual site. (C)SOTSU・SUNRISE
The aim of the BANDAI HOBBY STORE is to expand the BANDAI SPIRITS plastic model business in Europe by offering Europe's largest selection of GUNPLA. In addition to GUNPLA and GUNDAM-related products from the BANDAI NAMCO Group, the store will also offer many other plastic models, etc. from BANDAI SPIRITS.
The central Republic district where the new store will open is home to multiple shops selling games, anime, and comics, attracting users from all around France. Manga Story, the largest shop in the area, began selling BANDAI plastic models, focused on GUNPLA, around four years ago. Discussions with the president, Mr. Carosella regarding the possibility of opening a shop specializing in plastic models had been ongoing for some time, leading to the opening of this new store in the same area.
With about 200 square meters of space on the main floor and in the basement, the store will carry about 600 different types of plastic models, including both new and conventional products. With the various GUNPLA categories organized by color for ease of understanding, and a workshop area at the back of the store where customers can try assembling the models, everyone from child to adult, beginner to expert, will find a variety of ways to enjoy plastic models, from hands-on experience to purchase.
We will use the opening of this store as an opportunity to explore the possibility of opening multiple stores in the future.
|
Store Overview |
|
|
Name: |
BANDAI HOBBY STORE |
|
Location: |
5 boulevard Voltaire, 75011 Paris, France |
|
Business hours: |
Monday-Saturday 10:00-19:30 Closed Sundays |
|
Store area: |
Approximately 200 m2 |
|
Management: |
Manga Story |
|
Admission: |
Free |
What is "GUNPLA"?
GUNPLA are plastic models based on the GUNDAM series, launched in Japan in July 1980 and celebrating their 40th anniversary this year. So far, over 700 million units have been sold: 525.8 million from the Real series, and 174.4 million from the SD series (as of the end of May 2020), making GUNPLA the biggest hit in the history of plastic models. In recent years, we have been growing our overseas market.
Image download URL: https://bit.ly/ (this URL is valid for 30 days from the date of distribution)
* The information in this press release is current as of July 27, 2020, and is subject to change without notice.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200727005200/en/
Contact information
Press inquiries:
BANDAI S.A.S. Makoto Nishiyama (mnishiyama@bandai.fr)
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte’s Pivotal frontMIND Trial Showed Tafasitamab (Monjuvi ® /Minjuvi ® ) Combination Significantly Prolonged Progression-free Survival, Reducing the Risk of Disease Progression or Death by 25% in Patients with Previously Untreated, High-risk DLBCL30.5.2026 15:00:00 EEST | Press release
Incyte (Nasdaq:INCY) today announced positive results from the pivotal Phase 3 frontMIND trial evaluating the efficacy and safety of tafasitamab (Monjuvi®/Minjuvi®), a humanized Fc-modified cytolytic CD19-targeting monoclonal antibody, and lenalidomide added to R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone; Tafa-Len-R-CHOP) versus R-CHOP alone as a first-line treatment for adults with previously untreated diffuse large B-cell lymphoma (DLBCL) or high-grade B-cell lymphoma (HGBL). Eligible patients had an International Prognostic Index (IPI) score of 3-5, or, for patients ≤60 years of age, an age-adjusted IPI (aaIPI) of 2-3. The oral presentation of these data is taking place at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting being held May 29 – June 2, 2026, in Chicago (Abstract #LBA7000. Session: Oral Abstract Session – Hematologic Malignancies – Lymphoma and Chronic Lymphocytic Leukemia. May 30, 4:00 – 7:00 p.m. ET [3:00 – 6:00 p.m.
Fortegra Completes Acquisition by DB Insurance29.5.2026 23:30:00 EEST | Press release
The Fortegra Group, Inc. ("Fortegra"), a global specialty insurance company, today announced the completion of its acquisition by DB Insurance Co., Ltd. ("DB"), one of Korea's leading property and casualty insurers. The transaction, announced on September 26, 2025, received all required regulatory and stockholder approvals. Fortegra will operate independently, maintaining its existing leadership team, distribution relationships, and underwriting discipline. Agents, distribution partners, and customers will continue to experience the service excellence that has defined the Fortegra experience. Richard Kahlbaugh, Chairman and CEO of Fortegra, said: "Every company eventually changes ownership. That is the nature of business. The closing of this acquisition is a starting point. As part of DB Insurance, Fortegra is positioned to expand our business geographically, enhance our capabilities and deepen our market presence in the US, Europe, the United Kingdom and Asia. Together, DB Insurance a
SINOVAC Receives Nasdaq Notification Regarding Late Filing of 2025 Annual Report29.5.2026 23:01:00 EEST | Press release
Sinovac Biotech Ltd. (Nasdaq: SVA) (“SINOVAC” or the “Company”), a leading provider of biopharmaceutical products in China, today announced that it received a notification letter dated May 20, 2026 (the “Notification Letter”), from Nasdaq Listing Qualifications (“Nasdaq”) stating that as of May 8, 2026, the Company had regained compliance with the periodic filing and interim financial requirements in Nasdaq Listing Rules 5250(c)(1) (the “Periodic Filing Rule”) and 5250(c)(2), as required by the Panel’s decision dated January 21, 2026. As previously disclosed on January 22, 2026, under the Panel’s decision, SINOVAC was required to, on or before May 11, 2026, demonstrate compliance with such Nasdaq Listing Rules by completing filings of its annual report for the year ended December 31, 2024, on Form 20-F and an interim balance sheet and income statement as of the end of its second quarter of 2025 on Form 6-K. The Company timely completed such filings as required by the Panel’s decision.
From Network Automation to Agentic NetOps: NetBrain Sets the Standard for Deploying AI in Network Operations29.5.2026 16:00:00 EEST | Press release
NetBrain Technologies, Inc. today announced major new platform features that advance Agentic NetOps from an emerging category to operational reality. NetBrain's clients are already deploying agents that are diagnosing and remediating issues across complex multi-vendor enterprise networks. These new features further extend the platform with new agent tooling, cross-domain context, and open interfaces for the broader agentic enterprise. Early customer outcomes show the magnitude of the shift: A leading health insurer used NetBrain's Deep Diagnosis agent to diagnose and resolve a weeks old VPN connectivity issue in under five minutes. A large manufacturer resolved a critical device issue with a single prompt, isolating the root cause across the network path in under 20 minutes, saving hundreds of hours of engineer time, shrinking MTTR by more than 95%. A global telecommunications firm found NetBrain's context-grounded agents outperformed a stand-alone frontier LLM on a persistent firewall
Adtran resolves long-running patent litigation, reinforcing commitment to defend innovation29.5.2026 15:00:00 EEST | Press release
Adtran today announced it has resolved a patent litigation matter, resulting in a full settlement and dismissal of all claims with prejudice. The case, initiated in 2020 by a non-practicing entity asserting five patents, was transferred to the US District Court for the Northern District of Alabama in 2021 following a successful motion by Adtran. Adtran subsequently filed counterclaims, including bad-faith patent assertion under Alabama statutory law. The settlement includes payment to Adtran to resolve its counterclaims. Terms of the agreement remain confidential. “This outcome reflects a disciplined and consistent approach to protecting our innovation and our customers,” said Justin Ferguson, SVP and general counsel at Adtran. “We take all claims seriously, but we will not hesitate to defend ourselves when assertions lack merit. Situations like this place unnecessary strain on technology providers and divert resources from advancing networks and services. By advancing our counterclaim
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom